Although a defect in renal transport of phosphate seems well established as the primary abnormality underlying the pathogenesis of X-linked hypophosphatemic rickets and osteomalacia, several observations indicate that renal phosphate wasting and hypophosphatemia cannot solely account for the spectrum of abnormalities characteristic of this disease. Thus, in the present study, we investigated the potential role of abnormal vitamin D metabolism in the pathogenesis of this disorder and the effect of 1,25-dihydroxyvitamin D 3 therapy on both the biochemical abnormalities characteristic of this disease and the osteomalacia. Four untreated patients, ages 14-30 yr, had normocalcemia (9.22±0.06 mg/dl); hypophosphatemia (2.25±0.11 mg/dl); a decreased renal tubular maximum for the reabsorption of phosphate per liter of glomerular filtrate (2.12±0.09 mg/dl); normal serum immunoreactive parathyroid hormone concentration; negative phosphate balance; and bone biopsy evidence of osteomalacia. The serum 25-hydroxyvitamin D 3 concentration was 33.9±7.2 ng/ml and, despite hypophosphatemia, the serum level of 1,25-dihydroxyvitamin D 3 was not increased, but was normal at 30.3±2.8 pg/ml. These data suggested that abnormal homeostasis of vitamin D metabolism might be a second defect central to the phenotypic expression of X-linked hypophosphatemic rickets/osteomalacia. This hypothesis was supported by evaluation of the long-term response to pharmacological amounts of 1,25-dihydroxyvitamin D 3 therapy in three subjects. and the mineralization front activity. We, therefore, suggest that a relative deficiency of 1,25-dihydroxyvitamin D3 is a factor in the pathogenesis of X-linked hypophosphatemic rickets and osteomalacia and may modulate the phenotypic expression of this disease.
INTRODUCTION
X-linked hypophosphatemic rickets and osteomalacia (XLH)' is a familial syndrome characterized by inadequate mineralization of cartilage and/or bone, conse-quent skeletal deformities, and growth retardation. The hallmarks of this disease include a reduced serum concentration of inorganic phosphate (Pi) (1) (2) (3) and resistance to therapy with vitamin D (4) (5) (6) . Current evidence suggests that the primary defect governing the genesis of XLH is an abnormality of Pi transport in the renal tubule (7) . This abnormal function results in Pi wasting and consequent hypophosphatemia, upon which all other components of the disorder apparently depend.
Despite the established primacy of renal Pi wasting in the pathogenesis of XLH, treatment aimed only at overcoming the resulting hypophosphatemia fails to normalize all of the manifestations of the disease (8, 9) , indicating that an additional factor(s), or an alternate physiological abnormality, may contribute to the pathogenesis of this disorder. Traditionally, an alteration of vitamin D-dependent calcium homeostasis has been suspected as such a potential abnormality (10) . However, the presence and/or nature of this suspected defect remains undetermined. Nevertheless, the recent elucidation of the metabolic pathways for vitamin D activation (11, 12) has focused interest on the possibility that an abnormality in this process may be operative in XLH.
Therefore, in the present investigation, we studied whether compromised availability of vitamin D or its active metabolite, 1,25(OH)2D3, is a factor in the pathogenesis ofXLH. In these studies we performed detailed examination of vitamin D metabolism in untreated subjects with XLH and, in addition, evaluated the effects of long-term 1,25(OH)2D3 therapy on the biochemical and bone histomorphological abnormalities characteristic of this disease.
METHODS
Patient population. Four patients, a female aged 15 yr and three males, 14, 21 , and 30 yr of age (cases 1-4, respectively) were selected for study. The adolescent subjects were probands from kindreds with an X-linked dominant transmission of the rachitic-osteomalacic disorder and the adult males were brothers in a third kindred in which XLH had been likewise documented.
At the initiation of the study the chronologically aged 15-and 14-yr-old subjects had a height age of 12 and 11 yr and a bone age (13) of 17 and 16 yr, respectively. In addition, premature fusion of the epiphyseal centers in the distal femur and proximal tibia had occurred in both subjects and consequently there was no evidence of active rickets. However, characteristic postrachitic skeletal deformities were present and there was radiographic evidence of active osteomalacia. At the completion of the 1-yr study, height age in these subjects was unchanged whereas bone age was 17 yr in both subjects. The adult subjects (cases 3 and 4) likewise presented with growth retardation (height 155 and 163 cm) and postrachitic deformities. In addition, active osteomalacia was similarly evidenced radiographicallv by pseudo-fractures, coarsened trabeculation, and rarified areas in the long bones.
Therapy with pharmacological amounts of vitamin D and/or vitamin D and oral phosphates had been previously administered to each subject. Initiation of treatment was at age 5-8 yr of age and adherence sporadic therafter. However, no form of therapy with oral Pi or vitamin D and its metabolites had been administered to the patients for 4-9 yr before evaluation.
Complete metabolic studies and bone biopsies were performed in all four subjects in the untreated state on the Duke University Medical Center Clinical Research Unit. Subsequently, therapy with 1,25(OH)2D3 alone was initiated in cases [1] [2] [3] Table I ) by the colorimetric method of Dryer et al. (14) . Serum creatinine (normal 0.7-1.2 mg/dl) and alkaline phosphatase were determined on the Multichannel Technicon Autoanalyzer (Technicon Instruments Corp., Tarrytown, N. Y.). Urine specimens were stored at -20°C before analysis of calcium (by atomic absorption spectrophotometry), Pi (15) , and creatinine (16) . Fecal fat excretion was determined by the method of Van de Kamer et al. (17) on 72-h fecal collections marked by carmine red dye and collected during ingestion of 70 g fat/d. Serum parathyroid hormone (PTH) concentration was measured by four separate radioimmunoassays. Carboxyterminal-specific assays were purchased from the Mayo Medical Laboratory (Rochester, Minn.) and The Upjohn Laboratory (Kalamazoo, Mich.); normals were <40 ul eq/ml (18) and <150-375 pg eq/ml (19) , respectively. An aminoterminal-specific assay (normal < 0.125 ng/ml) employing a guinea pig antibody raised against the synthetic (1-34) aminoterminal peptide of human PTH was performed in the Duke University Laboratories (20, 21) and Dr. Leonard Deftos (University of Califomia, La Jolla, Calif.) measured PTH (normal < 300 pg/ml) by a predominantly carboxy-terminal immunoassay employing previously published methods (22 (29) . For these studies serial 2-h urine collections on selected mornings were preceded by a water load of 20 ml/kg body wt. The urine Pi (15) and creatinine (16) were determined in each specimen, serum determinations of P, (14) and creatinine at the midpoint of each collection, and the TmP/GFR estimated (for age-specific normals, see Table I ) by appropriate calculations and use of a published nomogram (30 to assess whether the XLH mutation is associated with decreased availability of either of these metabolites. The serum 25(OH)D concentration averaged 33.9±7.2 ng/ml and was within the normal range in each subject (Table I) , indicating normal vitamin D stores and providing evidence for normal vitamin D-25-hydroxylase activity. However, despite the presence of hypophosphatemia, which is a known stimulus of 25-hydroxyvitamin D-la-hydroxylase activity, the serum 1,25-(OH)2D concentration averaged 30.3±2.8 pg/ml and was marginally below or within the appropriate agematched normal range in each adolescent and adult subject (Table I) (Table I) . In response to therapy with 1,25(OH)2D3 the serum Pi was significantly elevated in each treated subject (P < 0.001) and approached, or was within, the age-corrected normal range. Similarly, 1,25(OH)2D3 therapy resulted in a significant increase (P < 0.01) of the TmP/GFR (Table I) . However, the TmP/GFR remained subnormal in each subject.
An additional abnormality of Pi metabolism manifest at presentation was a negative Pi balance, which ranged from -3 to -60 mg/d (Table II) . This abnormality resulted from apparent net gastrointestinal malabsorption of Pi (Table II) and renal Pi wasting (TmP/ GFR, 2.12+0.09 mg/dl) ( Table I) . Treatment with 1,25(OH)2D3 resulted in a remarkably positive Pi balance, ranging from + 144 to +264 mg/d in the treated subjects (Table II) . This alteration in Pi balance was largely caused by a significant improvement in the net gastrointestinal absorption of Pi in each subject (Table  II) and renal Pi wasting (TmP/GFR, 2.43±0.06) (Table  I) . Despite the improvement in renal Pi wasting, however, 24-h urine P i increased significantly in response to therapy (Table II) .
Effects of 1,25(OH)2D3 therapy on calcium metabolism. In the base-line period the serum calcium concentration averaged 9.22+0.06 mg/dl, a value well within normal limits. After treatment with 1,25(OH)2-D3 the mean serum calcium remained normal, 9.27 +0.23 mg/dl, and was not significantly different from the base-line level. However, in case 2, a significant increase, and in case 3, a significant decrease in the serum calcium did occur and persisted (Table I) .
Further analysis of calcium homeostasis revealed that the patients maintained a marginally positive calcium balance, 83+30 mg/d, in the base-line period (Table III) . This positive balance was maintained, despite a modest decrease in net gastrointestinal malabsorption of calcium, by virtue of renal conservation of calcium (Table III) . Treatment with 1,25(OH)2D3 resulted in markedly positive calcium balance of 438+30 mg/d (Table III) . This calcium retention occurred in response to a significant increase in net gastrointestinal absorption of calcium in each treated subject and despite an increase in urinary calcium excretion (Table III) Table V ). Moreover, typical of the bone abnormality in XLH, osteocytic osteolysis was uniformly present (Fig. 1) . In contrast, after 6 and 12 mo of therapy an apparent resolution of the mineralization defect had occurred. Bone biopsies from each treated subject were marked by a significant increase in tetracycline-labeled mineralization front activity (Fig. 2) and an apparent decrease in the osteocytic osteolysis. This apparent bone healing was accompanied by a significant decline in the serum alkaline phosphatase activity in each treated patient (Table I) (Table V) . Further, this metabolite and mineralization front activity ( (38, 39) ; and (c) animals rendered hypophosphatemic by Pi depletion develop abnormalities in bone mineralization similar to those of XLH (40) . Moreover, Tenenhouse et al. (41) have reported that purified renal cortical brush membranes from the murine homologue of XLH, the X-linked hyp-mouse, exhibit a partial loss of the sodium-dependent phosphate transport process. This finding in the hyp-mouse is compatible with a partial loss of renal phosphate transport in XLH. Nevertheless this hypothetical Pi leak and resultant hypophosphatemia do not account for all of the abnormalities of XLH, especially the characteristic decrease in intestinal absorption of calcium and P1 or its normalization after therapy with la(OH)D3 (42, 43) . In addition, the variable presence of the bone lesion and the lack of correlation between the magnitude of the hypophosphatemia and the severity of the rickets or osteomalacia is enigmatic (1) . Finally, treatment with P1 alone or in combination with pharmacological amounts The therapeutic response to pharmacological amounts of 1,25(OH)2D3 substantiates a role for altered vitamin D homeostasis in the pathogenesis of XLH. Therapy raised the serum 1,25(OH)2D level and partially restored Pi homeostasis; long-term treatment normalized the mineralization defect in bone. The effects of therapy on Pi homeostasis were apparently modulated by the direct action of 1,25(OH)2D3 on a variety of tissues. These included a marked increase in the net gastrointestinal absorption of Pi (Table II) , an apparent suppression of PTH secretion (Table IV); and an amelioration of renal Pi wasting, indicated by a significant increase in TmP/GFR (Table I) .
However, the concomitant increase in serum Pi (Table  I ) and consequently in the filtered load of Pi, significantly increased the 24-h urine Pi excretion (Table  II) obscuring any effects on renal Pi reabsorption. In any case, the TmP/GFR remained below the normal range and the 24-h urine P1 significantly above that in the base-line state, indicating persistent and inappropriate Pi wasting. Thus, 1,25(OH)2D3 treatment did not correct the basic renal defect, but did alter Pi homeostasis to circumvent the abnormality and to achieve a positive Pi balance (Table II) and a significant increase in the serum Pi.
Most importantly, however, 1,25(OH)2D3 therapy repaired the osteomalacic bone lesion. Treatment restored normal mineralization front activity to the endosteal bone surface, reversing a primary abnormality ofthe XLH osteomalacic disorder. Moreover, the linear correlation between mineralization front activity and the serum level of 1,25(OH)2D3 (Fig. 3) indicates that this metabolite may directly affect deposition of calcium in bone. Although this relationship may be indirect and modulated by other factors, the lack of correlation between serum Pi at the time ofbone biopsy and mineralization front activity (data not shown) and the failure of alternate therapeutic means to cause this response (44), despite similar effects on the characteristic biochemical abnormalities of the syndrome, suggest that the action on bone is direct. Moreover the apparent need to achieve supraphysiological serum levels of 1,25(OH)2D to effect bone healing reaffirms the hypothesis that an abnormality of vitamin D metabolism contributes to the manifestations of XLH (Tables I-III) when we used pharmacological amounts of 1,25(OH),D3.
Further, in each treated subject in the present study the circulating concentration of 1,25(OH)2D3 increased significantly in response to pharmacological doses of this metabolite, attaining supraphysiological levels ( Table I) . While the values in the adolescent patients remained within the chronologically age-matched normal range (23-70 pg/ml), they were above values (23-48 pg/ml) maintained in normals matched for bone I- (62) . A persistent defect in this function would result in incomplete healing of the osteomalacia. Thus, at present we cannot predict whether 1,25(OH)2D3 therapy resolves the osteomalacic disorder of XLH. Nevertheless, our data do illustrate that 1,25(OH)2D3 therapy normalizes mineralization front activity which is a primary defect underlying the bone abnormalities in XLH.
Thus, our studies suggest that altered regulation of vitamin D metabolism is a fundamental abnormality in XLH. Whether the resulting 'deficiency' of 1,25-(OH)2D is secondary to decreased biosynthesis or increased degradation remains to be determined. However, at the present time we propose that the sequence of metabolic events underlying this disorder includes: (a) a genetic lesion in the renal tubule results in Pi wasting and consequent hypophosphatemia; (b) the hypophosphatemia fails to elicit the anticipated increase in 1,25(OH)2D3 biosynthesis; and (c) relative deficiency of 1,25(OH)2D3 and associated absolute deficiency of Pi result in gastrointestinal malabsorption of calcium and Pi and, most importantly, in the characteristic defect in mineralization front activity in XLH bone. Although additional defects are likely to be revealed with further studies, our findings indicate that therapeutic regimens which include 1,25(OH)2D3 may be beneficial in this refractory disorder.
